Day: June 29, 2023

To Nasdaq Copenhagen                                                 29 June 2023         Nykredit Realkredit A/S upgrades full-year guidanceThe Nykredit Group raises its guidance for 2023 and now expects profit after tax for 2023 of DKK 9.75-10.75 billion compared with the previously guided range of DKK 9-10 billion. The first six months were driven by continued business and customer growth across the board, and we recorded growth in bank lending among our largest corporate clients. Further, we recorded highly satisfactory growth in the underlying business, partly driven by higher interest rates. The earnings upgrade is also the result of the continued strong credit quality and resilience of our customers, which has led to a minor reversal of loan impairments. Michael Rasmussen, Group Chief Executive, says: – Our financial performance...

  Vaccines Investor EventVaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal diseaseSanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030, fueled by an accelerated pace of innovation Intent to start at least 5 innovative Phase 3 vaccine programs by 2025Paris, June 29, 2023. Today Sanofi is hosting a Vaccines Investor Event dedicated to its pipeline with key members of its leadership team. The event will highlight how Sanofi’s strategy is supported by vaccines R&D. Since 2019, reinvesting in key growth drivers and a renewed pipeline has positioned the company well as it moves at speed on the second phase of its Play to Win strategy. Sustained growth in the vaccines business will be driven by core franchises of influenza, meningitis, and pediatric vaccines, with the addition...

SHANGHAI, China, June 29, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the U.S. Food and Drug Administration (“FDA”) has recently agreed a randomized, double-blind, placebo-controlled, multi-regional phase 3 clinical study of tifcemalimab (product code: TAB004/JS004), an anti-BTLA monoclonal antibody used in combination with toripalimab, an anti-PD-1 monoclonal antibody, as consolidation therapy for patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy may proceed. Junshi Biosciences will officially initiate the phase 3 clinical study in the near future. According...

29 June 2023 PRESS RELEASE Ad hoc announcement pursuant to Art. 53 Listing Rules: GAM announces the sale of its third-party Fund Management Services businesses to Carne Group GAM has entered into definitive agreements to sell its loss-making third-party fund management services businesses in Luxembourg and Switzerland (“FMS Businesses”) to Carne Group (“the Transactions”). The GAM Board believes that the Transactions are in the interests of all stakeholders of GAM and represent the implementation of an important part of the Board’s strategic review. The purchase price, which reflects the reduced assets under management (“AuM”) and loss-making nature of the FMS Businesses, is EUR 2.25 million for the Luxembourg business and CHF 0.5 million for the Swiss business, both subject to adjustment based on revenue run rates at closing. In addition,...

VEON reveals faster local currency revenue and EBITDA growth in first five months at AGM Amsterdam, 29 June 2023 07:00 CEST – VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, will report its key financial highlights for the first five months of 2023 (“5M23”) at the annual general meeting of shareholders (“AGM”) being held today. During April and May 2023, VEON Group demonstrated accelerated growth in local currency revenues, achieving a 19.0% year-on-year increase. These results have solidified the strong year-to-date performance. While reported currency revenues for the first five months of 2023 saw a 7.6% decline compared to the previous year, local currency revenues increased by 16.8% year-on-year. Notably, five out of our six countries...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, June 29, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the timeline of the reverse share split in the ratio 10:1 which was approved by shareholders at the Annual General Meeting held on June 27, 2023, with a large majority.June 30, 2023: Last trading day of old shares (ISIN: CH0027148649) on SIX Swiss Exchange July 3, 2023: First trading day of new shares (ISIN: CH1276028821) on SIX Swiss Exchange (ex-date)The reverse share split may result in fractions of new registered shares of the Company for individual shareholders. This is the case if shareholders hold a number of Santhera shares that is not divisible by 10 as of June 30, 2023....

WISeKey Launches an Upgraded Version of its WISeID Digital Identity and Privacy Platform Geneva and Zug Switzerland – June 29, 2023 – WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN; Nasdaq: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) solutions, announced today a major upgrade to its innovative digital identity and privacy platform, WISeID.com, designed to provide users with enhanced protection against identity theft and increase privacy in today’s hyper-connected digital world. The new generation of WISeID builds upon WISeKey’s tradition of pioneering advanced cybersecurity solutions and introduces a suite of significant improvements to further secure users’ digital identities and personal data. NEW FREE IDENTITY VALIDATION: Now all WISeID users can verify their real identity...

Press Release June 29, 2023Renault Group upgrades its 2023 financial outlook Link to the conference call at 8:00am today (CEST) Given the current level of performance of the Group, which is above initial expectations, Renault Group upgrades its financial outlook for the full year 2023 and expects: a Group operating margin between 7% and 8% (versus superior or equal to 6% previously) an Automotive operational free cash flow superior or equal to €2.5 billion (versus superior or equal to €2 billion previously)This improvement is mainly driven by the quality of the sales mix thanks to the success of our new launches and to our commercial policy focused on value. Renault Group expects for the first half of 2023:a Group operating margin superior to 7% an Automotive operational free cash flow around €1.5 billion (including €600 million...

BERKELEY HEIGHTS, N.J., June 28, 2023 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the pricing of its previously announced underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $4.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 2,500,625 shares of its common stock at a price of $3.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The total gross proceeds from the offering to the Company are expected to be...